IMPlementation of gUideLines for the Management of Arterial hypertenSION. The IMPULSION Study

NCT ID: NCT00416611

Last Updated: 2009-01-29

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 1000 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2006-11-30
• Study Completion Date: 2007-11-30

Brief Summary

The objective of this protocol is to improve awareness, treatment, and control of arterial hypertension, within primary prevention of target organ damage, by implementing guidelines, after training of the participating physicians.

Detailed Description

Physicians from 20 hospitals and 40 health centres (primary health care settings) were trained to implement guidelines in treating arterial hypertension.

There will be a baseline recording of patients with arterial hypertension and then physicians will have to complete a one page form (by ticking pre-specified boxes) about the baseline status of the patients and will have to report the measures they took to improve awareness, treatment, and effective control of arterial hypertension. After a six month effort, physicians will have to complete the same form at study completion. Previous training of physicians and the fact that they will have to report their success in treating hypertension will hopefully contribute to an increase in number of hypertensive patients at blood pressure target, and will minimise the target organ damage. The estimated reduction in coronary heart disease risk will be evaluated by a comparison of this risk (as evaluated by a risk engine, i.e. PROCAM) at study completion with that of baseline.

Conditions

High Blood Pressure

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Interventions

Implementation of guidelines

Intervention Type: BEHAVIORAL

Eligibility Criteria

Inclusion Criteria

• Arterial hypertension as defined by the JNC 7 report

Exclusion Criteria

• Pregnancy
• Lactation
• Malignancies with small life expectancy
• Unwillingness to participate

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Hellenic Atherosclerosis Society

OTHER

Sponsor Role: lead

Responsible Party

V. Athyros, MD member of Advisdory Board of Hellenic Atherosclerosios Society

Principal Investigators

Athyros G Athyros, MD

Role: STUDY_DIRECTOR

Clinical Trials Chair of Hellenic Atherosclerosis Society

Locations

Hellenic Atherosclerosis Society

Thessaloniki, Thessaloniki, Greece

Countries

Greece

References

Karagiannis A, Athyros VG, Papageorgiou A, Tziomalos K, Elisaf M. Should atenolol still be recommended as first-line therapy for primary hypertension? Hellenic J Cardiol. 2006 Sep-Oct;47(5):298-307. No abstract available.

Reference Type: RESULT

PMID: 17134065 (View on PubMed)

Karagiannis A, Hatzitolios AI, Athyros VG, Deligianni K, Charalambous C, Papathanakis C, Theodosiou G, Drakidis T, Chatzikaloudi V, Kamilali C, Matsiras S, Matziris A, Savopoulos C, Baltatzi M, Rudolf J, Tziomalos K, Mikhailidis DP. Implementation of guidelines for the management of arterial hypertension. The impulsion study. Open Cardiovasc Med J. 2009 May 5;3:26-34. doi: 10.2174/1874192400903010026.

Reference Type: DERIVED

PMID: 19557149 (View on PubMed)

Other Identifiers

HAS-02-231206

Identifier Type: -

Identifier Source: org_study_id